The type III transforming growth factor-β receptor inhibits proliferation, migration, and adhesion in human myeloma cells

Molecular Biology of the Cell

Volumn 22, Issue 9, 2011, Pages 1463-1472

  Lambert, Kathleen E ^a   Huang, Huang ^b   Mythreye, Karthikeyan ^a   Blobe, Gerard C ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b DUKE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; CYCLIN DEPENDENT KINASE INHIBITOR 1; CYCLIN DEPENDENT KINASE INHIBITOR 1B; ENDOGLIN; INTERLEUKIN 6; LIGAND; SHORT HAIRPIN RNA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 3; VASCULOTROPIN;

APOPTOSIS; ARTICLE; BONE MARROW CELL; BREAST CANCER; CELL ADHESION; CELL GROWTH; CELL INTERACTION; CELL MIGRATION; CELL MOTILITY; CELL PROLIFERATION; COCULTURE; CONTROLLED STUDY; DISEASE COURSE; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; INHIBITION KINETICS; LUNG CANCER; MULTIPLE MYELOMA; MYELOMA CELL; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN FUNCTION; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; STROMA CELL;

BONE MARROW CELLS; CELL ADHESION; CELL DIFFERENTIATION; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; COCULTURE TECHNIQUES; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLIN-DEPENDENT KINASE INHIBITOR P27; DISEASE PROGRESSION; HEMATOPOIESIS; HUMANS; IMMUNOBLOTTING; MULTIPLE MYELOMA; PROTEOGLYCANS; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; SIGNAL TRANSDUCTION; STROMAL CELLS;

EID: 79955506264     PISSN: 10591524     EISSN: 19394586     Source Type: Journal    
DOI: 10.1091/mbc.E10-11-0877     Document Type: Article

References (43)

1. Amoroso SR, Huang N, Roberts AB, Potter M, Letterio JJ (1998). Consistent loss of functional transforming growth factor b receptor expression in murine plasmacytomas. Proc Natl Acad Sci USA 95, 189-194. (Pubitemid 28103929)
2. Blobe GC, Liu X, Fang S, How T, Lodish HF (2001). A novel mechanism for regulating transforming growth factor beta (TGF-β) signaling. Functional modulation of type III TGF-β receptor expression through interaction with the PDZ domain protein, GIPC. J Biol Chem 276, 39608-39617.
3. Brenner H (2002). Long-term survival rates of cancer patients by the end of the 20th century: a period analysis. Lancet 360, 1131-1135.
4. Brown CB, Boyer AS, Runyan RB, Barnett JV (1999). Requirement of type III TGF-β receptor for endocardial cell transformation in the heart. Science 283, 2080-2082.
5. Chen W, Kirkbride KC, How T, Nelson CD, Mo J, Frederick JP, Wang X-F, Lefkowitz RJ, Blobe GC (2003). β-arrestin 2 mediates endocytosis of type III TGF-β receptor and down-regulation of its signaling. Science 301, 1394-1397. (Pubitemid 37075818)
6. Datto MB, Yu Y, Wang X-F (1995). Functional analysis of the transforming growth factor beta responsive elements in the WAF1/Cip1/p21 promoter. J Biol Chem 270, 28623-28628.
7. st ed., ed. JR Berenson, Totowa, NJ: Humana Press, 69-91.
8. Dong M, Blobe GC (2006). Role of transforming growth factor beta in hematologic malignancies. Blood 107, 4589-4596. (Pubitemid 43882602)
9. Dong M, How T, Kirkbride KC, Gordon KJ, Lee JD, Hempel N, Kelly P, Moeller BJ, Marks JR, Blobe GC (2007). The type III TGF-β receptor suppresses breast cancer progression. J Clin Invest 117, 206-217. (Pubitemid 46048467)
10. Elbendary A, Berchuck A, Davis P, Havrilesky L, Blast JR, Iglehart JD, Marks JR (1994). Transforming growth factor beta 1 can induce CIP1/WAF1 expression independent of the p53 pathway in ovarian cancer cells. Cell Growth Differ 5, 1301-1307. (Pubitemid 24381518)
11. Fernandez T, Amoroso S, Sharpe S, Jones GM, Bliskovski V, Kovalchuk A, Wakefield LM, Kim SJ, Potter M, Letterio JJ (2002). Disruption of transforming growth factor β by novel ligand-dependent mechanism. J Exper Med 195, 1247-1255. (Pubitemid 34564327)
12. Finger EC, Turley RS, Dong M, How T, Fields TA, Blobe GC (2008). TβRIII suppresses non-small cell lung cancer invasiveness and tumorigenicity. Carcinogenesis 3, 528-535. (Pubitemid 351404868)
13. Gordon KJ, Dong M, Chislock EM, Fields TA, Blobe GC (2008). Loss of type III transforming growth factor β receptor expression increases motility and invasiveness associated with epithelial to mesenchymal transition during pancreatic cancer progression. Carcinogenesis 29, 252-262. (Pubitemid 351359663)
14. Hannon GJ, Beach D (1994). P15INK4B is a potential effector of TGF-β induced cell cycle arrest. Nature 371, 257-261.
15. Hayashi T et al. (2004). Transforming growth factor β receptor I kinase inhibitor down-regulates cytokine secretion and multiple myeloma cell growth in the bone marrow microenvironment. Clin Cancer Res 10, 7540-7546. (Pubitemid 39557515)
16. Hazlehurst LA, Damiano JS, Buyuksal I, Pledger WJ, Dalton WS (2000). Adhesion to fibronectin via b1 integrins regulates p27kip1 levels and contributes to cell adhesion mediated drug resistance (CAM-DR). Oncogene 19, 4319-4327.
17. Hempel N, How T, Cooper SJ, Green TR, Dong M, Copland JA, Wood CG, Blobe GC (2008). Expression of the type III TGF-β receptor is negatively regulated by TGF-β. Carcinogenesis 29, 905-912. (Pubitemid 351993040)
18. Hempel N, How T, Dong M, Murphy SK, Fields TA, Blobe GC (2007). Loss of betaglycan expression in ovarian cancer: role in motility and invasion. Cancer Res 67, 5231-5238. (Pubitemid 46997261)
19. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ (2007). Cancer statistics. CA Cancer J Clin 57, 43-66.
20. Johnson DW, Qumsiyeh M, Benkhalifa M, Marchuk DA (1995). Assignment of human transforming growth factor beta-1 type II and type III receptor genes (TGFBR1 and TGFBR3) to 9q33-34 and 1p32-33, respectively. Genomics 28, 356-357.
21. Kehrl JH, Roberts AB, Wakefield LM, Jakowlew S, Sporn MB, Fauci AS (1986). Transforming growth factor β is an important immunomodulatory protein for human B lymphocytes. J Immunol 137, 3855-3860. (Pubitemid 17215314)
22. Kirkbride KC, Ray BN, Blobe GC (2005). Cell surface coreceptors: emerging roles in signaling and human disease. Trends Biochem Sci 30, 611-621. (Pubitemid 41540081)
23. Kirkbride KC, Townsend TA, Bruinsma MW, Barnett JV, Blobe GC (2008). Bone morphogenetic proteins signal through the transforming growth factor-b type III receptor. J Biol Chem 283, 7628-7637.
24. OLi CY, Suardet I, Little JB (1995). Potential role of WAF1/Cip1/p21 as a mediator of TGF-β cytoinhibitory effect. J Biol Chem 270, 4971-4974.
25. Lopez-Casillas F, Payne HM, Andres JL, Massagué J (1994). Betaglycan can act as a dual modulator of TGF-β access to signaling receptors: mapping of ligand binding and GAG attachment sites. J Cell Biol 124, 557-568. (Pubitemid 24064466)
26. Margulis V, Maity T, Zhang XY, Cooper SJ, Copland JA, Wood CG (2008). Type III transforming growth factor-β (TGF-β) receptor mediates apoptosis in renal cell carcinoma independent of the canonical TGF-β signaling pathway. Clin Cancer Res 18, 5722-5730.
27. Massague J, Blain SW, Lo RS (2000). TGF-β signaling in growth control, cancer, and heritable disorders. Cell 103, 295-309.
28. Mattioli M et al. (2005). Gene expression profiling of plasma cell dyscrasias reveals molecular patterns associated with distinct IGH translocations in multiple myeloma. Oncogene 24, 2461-2473. (Pubitemid 40593037)
29. Mythreye K, Blobe GC (2009). The type III TGF-b receptor regulates epithelial and cancer cell migration throughb-arrestin2-mediated activation of cdc42. Proc Natl Acad Sci USA 20, 8221-8226.
30. Ragnarsson G, Eiriksdottir G, Johannsdottir JTh, Jonasson JG, Egilsson V, Ingvarsson S (1999). Loss of heterozygosity at chromosome 1p in different solid human tumours: association with survival. Br J Cancer 79, 1468-1474. (Pubitemid 29116806)
31. Roberts AB, Wakefield LM (2003). The two faces of transforming growth factor β in carcinogenesis. Proc Natl Acad Sci USA 100, 8621-8623.
32. Shaughnessy JD et al. (2007). A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. Blood 109, 2276-2284.
33. Stenvers KL, Tursky ML, Harder KW, Kountouri N, Amatayakul-Chantler S, Grail D, Small C, Weinberg RA, Sizeland AM, Zhu HJ (2003). Heart and liver defects and reduced transforming growth factor β2 sensitivity in transforming growth factor β type III receptor-deficient embryos. Mol Cell Biol 23, 4371-4385. (Pubitemid 36666437)
34. Taniwaki M, Nishida K, Takashima T, Nakagawa H, Fujii H, Tamaki T, Shimazaki C, Horiike S, Misawa S, Abe T (1994). Nonrandom chromosomal rearrangements of 14q32.3 and 19p13.3 and preferential deletion of 1p in 21 patients with multiple myeloma and plasma cell leukemia. Blood 84, 2283-2290. (Pubitemid 24296390)
35. Teoh G, Anderson KC (1997). Interaction of tumor and host cells with adhesion and extracellular matrix molecules in the development of multiple myeloma. Hematol Oncol Clin North Am 11, 27-42. (Pubitemid 27147744)
36. Turley RS, Finger EC, Hempel N, How T, Fields TA, Blobe GC (2007). The type III transforming growth factor-β receptor as a novel tumor suppressor in prostate cancer. Cancer Res 67, 1090-1098.
37. Uchiyama H., Barut BA, Mohrbacher AF, Chauhan D, Anderson KC (1993). Adhesion of human myeloma-derived cell lines to bone marrow stromal cells stimulates interleukin-6 secretion. Blood 82, 3712-3720. (Pubitemid 24006055)
38. Urashima M, Ogata A, Chauhan D, Hatziyanni M, Vidriales MB, Dedera DA, Schlossman RL, Anderson KC (1996). Transforming growth factor-β1: differential effects on myeloma versus normal B cells. Blood 87, 1928-1938. (Pubitemid 26068909)
39. Wang LH, Yang XY, Zhang X, Farrar WL (2007). Inhibition of adhesive interaction between multiple myeloma and bone marrow stromal cells by PPARγ cross-talk with NFκB and C/EBPβ. Blood 110, 4373-4382.
40. Warner BJ, Blain SW, Seone J, Massague J (1999). Myc down-regulation by transforming growth factor beta required for activation of the p15(Ink4b) G(1) arrest pathway. Mol Cell Biol 19, 5913-5922. (Pubitemid 29399296)
41. Yasui H, Hideshima T, Richardson PG, Anderson KC (2006). Novel therapeutic strategies targeting growth factor signaling cascades in multiple myeloma. Br J Haematol 132, 385-397. (Pubitemid 43381614)
42. You JY, Bruinsma MW, How T, Ostrander JH, Blobe GC (2007). The type III TGF-β receptor signals through both Smad3 and p38 MAP kinase pathways to contribute to inhibition of proliferation. Carcinogenesis 12, 2491-2500. (Pubitemid 350238951)
43. Zhan F et al. (2006). The molecular classification of multiple myeloma. Blood 108, 2020-2028. (Pubitemid 44395016)